Biosense Webster Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biosense Webster Inc
The deal includes Baylis’ NRG and VersaCross transseptal access platforms which complement Boston Scientific’s catheter-based devices that require left-heart access.
Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.
The company is supporting two US trials of the AcQBlate Force ablation catheter to support FDA approval of the system to treat atrial flutter and atrial fibrillation.
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.
- Diagnostic Imaging Equipment & Supplies
Surgical Equipment & Devices
- Minimally or Less Invasive